Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.